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Abstract:	 The	 last	Brazilian	guidelines	 on	melanoma	were	published	 in	 2002.	Development	 in	diagnosis	 and	
treatment	made	updating	necessary.	The	coordinators	elaborated	ten	clinical	questions,	based	on	PICO	system.	A	
Medline	search,	according	to	specific	MeSH	terms	for	each	of	the	10	questions	was	performed	and	articles	selected	
were	classified	from	A	to	D	according	to	level	of	scientific	evidence.	Based	on	the	results,	recommendations	were	
defined	and	classified	according	to	scientific	strength.	The	present	Guidelines	were	divided	in	two	parts	for	edito-
rial	and	publication	reasons.	In	this	second	part,	the	following	clinical	questions	were	answered:	1)	which	patients	
with	primary	cutaneous	melanoma	benefit	from	sentinel	lymph	node	biopsy?	2)	Follow-up	with	body	mapping	is	
indicated	for	which	patients?	3)	Is	preventive	excision	of	acral	nevi	beneficious	to	patients?	4)	Is	preventive	exci-
sion	of	giant	congenital	nevi	beneficious	to	patients?	5)	How	should	stages	0	and	I	primary	cutaneous	melanoma	
patients be followed?
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INTRODUCTION
Cutaneous	melanoma	(CM)	is	one	of	 the	most	
potentially dangerous forms accounting for approxi-
mately 90% of deaths of skin cancers. The dermatol-
ogist is in the forefront of diagnosis and treatment of 
CM. It is his/her duty to keep updated on best prac-
tices	 in	 diagnosis,	 treatment	 and	 disease	 monitor-
ing	to	be	able	to	diagnose,	 treat	and	council	patients	
in	 the	best	way.	The	 last	Brazilian	guidelines	on	CM	
were published in 2002.1 Over 10 years have passed 
and during this period important advances in the area 
occurred,	 with	 greater	 relevance	 to	 diagnostic	 tech-
niques.	Although	some	concepts	have	not	changed,	it	
is necessary to update the standards of practice on this 
important health problem.
These guidelines are intended for diagnostic 
and therapeutic approach and follow-up of patients 
with	 suspected	 or	 confirmed	 diagnoses	 of	 primary	
CM	(PCM)	with	no	clinical	nor	histological	evidence	
of	metastatic	disease	(stages	0,	I	and	II).	They	do	not	
include ocular nor mucosal melanoma.
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OBJECTIVE
To introduce the most advanced evidences in 
diagnosis,	 therapeutic	 management	 and	 monitoring	
of	PCM	clinical	stages	0,	I	and	II	patients,	describing	
diagnostic	 peculiarities	 that	 allow	 identification	 of	
these	tumors	in	early	stages,	as	well	as	measures	most	
widely accepted for treatment and follow-up in the 
context	of	Brazilian	dermatology.
DESCRIPTION OF EVIDENCE COLLECTION METHOD
The	coordinators	have	defined	10	questions	that	
reflect	 issues	of	clinical	relevance	on	the	subject.	The	
questions	were	 structured	 according	 to	 the	 acronym	
PICO	(patient	or	population,	intervention,	comparison	
or	 control	and	outcome),	according	 to	 regulations	of	
the	National	Health	Agency,	the	Brazilian	Medical	As-
sociation	and	Federal	Council	of	Medicine,	described	
in	“The	process	of	development,	validation	and	imple-
mentation of clinical guidelines in the private health-
care	system	in	Brazil”.2	To	answer	 these	questions,	a	
literature	review	of	scientific	articles	was	conducted	in	
MEDLINE database. Search for evidence was limited 
primarily to articles published between 01/01/2009 
and	06/30/2014	and	keywords	(MeSH	terms)	present	
in	the	title	and/or	summary	were	used,	grouped	into	
specific	syntaxes	for	each	of	the	10	questions	alone,	as	
described in table 1.
After	 reading	 the	 abstracts,	 articles	 contain-
ing	information	relevant	to	the	subject	were	selected.	
When	appropriate,	references	present	in	these	papers	
were	 selected,	 without	 limit	 for	 publication	 period,	
and	were	 analyzed	 using	 the	 same	methodology	 as	
that for the primarily selected studies.
Articles	 that	 presented	 the	 expected	 contribu-
tion	were	analyzed	regarding	the	level	of	evidence	(Ta-
ble	2).	Recommendations	were	written	 in	response	 to	
the	questions	elaborated.	Recommendations	were	also	
graduated	according	to	level	of	evidence	(Table	2).
RESULTS AND DISCUSSION
1) Which patients with PCM benefit from per-
forming sentinel lymph node biopsy (SLNB)?
SLNB has been used for melanoma treatment 
since	1992.	At	first,	 it	was	believed	that	it	could	cure	
some	 cases,	 as	 well	 as	 reduce	 morbidity	 of	 radical	
lymphadenectomy that many patients had to undergo. 
With increased use and outcome of studies devoted to 
the	subject,	it	was	concluded	that	SLNB	does	not	inter-
fere	with	survival,	but	is	essential	for	staging	patients	
with melanoma as well as for regional control (level 
of	evidence	A).	There	are	two	main	advantages	in	pre-
cisely staging the disease: to determine which patients 
should	receive	adjuvant	therapy	and	to	provide	accu-
rate information to the patient about his disease.
A	 recent	 study,	 Multicenter	 Sentinel	 Lymph	
Node	 Trial-1	 (MSLT-1),	 showed	 no	 increase	 in	 mel-
anoma-specific	 survival	 among	 patients	 with	 PCM	
with Breslow thickness ranging from 1.2 to 3.5 mm 
submitted or not to SLNB.3	It	was	found,	however,	an	
increase in disease-free interval for both melanoma 
patients with intermediate thickness and for patients 
with	 thick	melanomas	 (Breslow	 thickness	>3.5	mm).	
3 This study also demonstrated that SLNB is a proce-
dure that properly stages and provides loco regional 
control,	i.e.,	avoids	extensive	lymphonodal	recurrenc-
es,	which	result	in	poorer	quality	of	life		(level	of	evi-
dence	A).
SLNB is also useful for determining which pa-
tients	 may	 benefit	 from	 adjuvant	 therapy.	Adjuvant	
treatment with pegylated interferon for patients with 
clinical examination or SLNB-evidenced lymph nodes 
was	 evaluated	 in	 a	 prospective,	 randomized	 study. 4 
In this initial study there was no improvement in sur-
vival	with	adjuvant	therapy.	In	further	data	analysis,	
however,	it	was	observed	that	patients	with	SLN	com-
promised by micrometastases and ulcerated primary 
Table 1:	Syntax	of	descriptors	used	to	research	each	question	and	number	of	selected	articles	
Question Syntax Number of articles
1	 Sentinel	lymph	node	biopsy	AND	melanoma	 385
2 (Follow-up	OR	monitoring)	AND	melanoma	AND	(total	body	photography	or	digital	dermoscopy) 49
3	 acral	nevus	AND	melanoma	 150
4	 Congenital	nevi	AND	melanoma	 36
5	 primary	melanoma	AND	follow-up	 94
Table 2: Grade of recommendation and level 
of evidence
A:		Experimental	or	observational	studies	of	higher	consist-
ency.
B:  Experimental or observational studies of lower consist-
ency.
C: Case reports/ uncontrolled studies.
D:		Opinion	without	critical	evaluation,	based	on	consen-
sus,	physiological	studies	or	animal	models.
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tumor	benefited	from	adjuvant	treatment	(level	of	ev-
idence	B). 5
For patients with thin melanomas (Breslow 
thickness	<1.00	mm)	positivity	 levels	obtained	when	
performing	SLNB	are	too	low	to	 justify	indication	of	
the procedure. In cases with thickness ranging from 
0.75	 mm	 to	 1.00	 mm,	 positivity	 is	 6%.	 6 In another 
study,	patients	with	Breslow	 thickness	 ranging	 from	
0.75 mm to 1.00 mm demonstrated 13% positivity 
when	ulceration	or	mitosis	were	present,	or	5%	when	
these	 factors	were	absent.	For	 the	group	as	a	whole,	
positivity was 8%. 7	Thus,	SLNB	can	be	 indicated	 in	
rare cases of thin melanoma associated with ulceration 
and/or	lymph	vascular	invasion	(level	of	evidence	B).
There	 is	 benefit	 in	 using	 SLNB	 for	melanoma	
with	mitotic	 index	 >1	 and	 Breslow	 thickness	 >	 0.75	
mm.	For	smaller	depths,	even	when	mitosis	are	pres-
ent,	SLNB	positivity	is	<5%,	making	SLNB	indication	
questionable	(level	of	evidence	B). 7
For	thick	melanomas	(≥3.5	mm)	MSLT-1	study	
showed	benefit	in	disease-free	time	and	loco	regional	
control	(level	of	evidence	B). 3
Recent studies show that presence of regression 
alone	is	not	indicative	for	performing	SLNB,	since	no	
statistical difference was found  when comparing cas-
es with or without regression. 7-8 The same occurs re-
garding Clark level 8-9	(level	of	evidence	B).
Recommendations:
•	  SLNB is indicated for patients with PCM with 
thickness	 ≥1.00	 mm,	 without	 palpable	 lymph	
nodes	(grade	of	recommendation	B).
•	  SLNB is indicated for patients with PCM with 
thickness <1.00 mm when ulceration and/or 
lymph vascular invasion are present (grade of 
recommendation	B).	
•	  SLNB is indicated for patients with PCM with 
thickness	between	≥0.75	mm	and	<1.00	mm	that	
present	one	or	more	mitosis	per	field	(grade	of	
recommendation	B).
•	  SLNB is indicated for patients with PCM with 
thickness	≥4.00	mm,	for	regional	control	(grade	
of	recommendation	B).
2)	Follow-up with body mapping is indicated for 
which patients?
Prior to discussion it is essential to clarify the 
difference	between	body	mapping	(BM)	and	follow-up	
with BM. BM is the name given to the combination of 
total body photographic documentation with digital 
dermoscopy of nevi.10 It is indicated for melanoma early 
diagnosis,	and	it	is	based	on	evaluation	of	dermoscopic	
features of the patient’s nevi. 11,12 When used as an iso-
lated	test,	performed	on	a	single	occasion,	it	works	just	
as	 a	 sole	dermatoscopic	 examination,	missing	one	of	
its	major	uses:	the	dynamic	observation	of	the	lesions.	
“Follow-up with BM” is based on the fact that benign 
lesions	tend	to	remain	stable	over	time,	in	contrast	to	
the expected evolution in melanomas.13	 In	 addition,	
follow-up with BM also allows early detection of new 
lesions,	not	identified	in	previous	exams.14-16
Isolated	 BM,	 not	 aimed	 at	 follow-up,	 is	 fre-
quently	used	in	Brazil	as	a	diagnostic	test	to	replace/	
complement dermoscopic examination usually per-
formed during dermatological consultations. This in-
dication	is	far	from	ideal,	but	is	justified	in	situations	
where dermoscopy of the entire body surface cannot 
be	performed	(level	of	evidence	D).
High-quality	 publications	 established	 param-
eters for indicating and performing follow-up with 
BM.10-24 Based	on	epidemiological	studies,	it	was	deter-
mined	that	patients	who	benefit	from	follow-up	with	
BM are those who are at increased melanoma risk (lev-
el	of	evidence	A).	18,21,22
Definition	of	 increased	melanoma	 risk	 is	 vari-
able.	Different	studies	on	the	subject	mention	individ-
ual risk factors. The most accepted ones are described 
in table 3. 16-33
Indication of follow-up with BM for individuals 
with	moderate	to	high	risk	is	 justified	by	the	greater	
efficiency	of	this	type	of	monitoring,	which	is	demon-
strated by the lower ratio between excised benign nevi 
during	follow-up	of	these	patients	(15:1),	compared	to	
79:1	 in	 low-risk	 (with	no	risk	 factors	 for	melanoma),	
patients. For low-risk patients follow-up with BM is 
not	indicated	because	it	reduces	the	specificity	of	the	
diagnosis and results in a greater number of unneces-
sarily	excised	benign	lesions	(level	of	evidence	B) 34-37
Table 3: Risk factors most associated with melanoma 
development
-  Presence of atypical nevus syndrome or at least one 
atypical nevus histologically diagnosed
-	Number	of	melanocytic	nevi	>50
-	Genetic	background	(if	known)
- Personal or family history of melanoma 
OTHER	RISK	FACTORS	RELATED	TO	MELANOMA	
DEVELOPMENT	TO	BE	CONSIDERED	
-	Fitzpatrick	phototype
- Personal history of non-melanoma skin cancer 
- Large number of ephelides
-	Hair	color	(red	presents	greater	risk)
- Light eyes
- History of sunburn in childhood
-	History	of	artificial	tanning	before	30	years	
Dermoscopic follow-up of isolated lesions 
(which	is	different	from	a	BM)	with	short	term	revalu-
ation,	however,	can	be	used	for	low-risk	patients	who	
have few lesions with some dermoscopic atypia with-
out initial clinical and dermoscopic criteria for mel-
anoma	 (level	 of	 evidence	A).	 In	 such	 cases,	 excision	
should	 also	be	 considered	as	 a	potentially	beneficial	
alternative	to	follow-up	(level	of	evidence	B).18-35
Iatrogenic	risk	factors,	such	as	immunosuppres-
sion	or	use	of	vemurafenib,	should	also	be	considered	
when indicating follow-up with BM (level of evidence 
B).38
In	 addition	 to	 defining	 which	 patients	 benefit	
from	 follow-up	with	 BM,	 optimal	 follow-up	 regimen	
was also studied. Two regimens (short and long term 
follow-up),	which	have	different	indications	and	objec-
tives,	are	the	most	accepted.	While	short	term	BM	fol-
low up is intended to reevaluate few lesions with some 
degree	of	suspicion,	long	term	BM	follow-up	is	indicat-
ed for multiple unsuspected lesions in individuals with 
multiple nevi.13,18	 When suspicious lesions at an early 
BM	 are	 identified,	 a	 revaluation	must	 be	 re-schedule	
within 2 to 4 months in order to detect short term der-
moscopic changes. This type of monitoring is more pre-
cise in identifyng featureless melanomas than the long 
term BM follow up. It also increases patient adherence 
39,40	 (level	 of	 evidence	 A).	 Patients	 undergoing	 short	
term follow-up with BM where no suspicious lesion 
was detected should be re-assessed every 6-12 months 
(level	of	evidence	A).10,13,19,20
The combination of short and long term fol-
low-up with BM is indicated because it allows dete-
ciont of a higher proportion of thin and in situ mela-
nomas than that expected in the general population 
(level	 of	 evidence	 A).13,18,20	 A	 recent	 meta-analysis	
demonstrated a greater melanoma detection probabil-
ity with longer follow-up.20 This	 fact	 justifies	perma-
nent	 monitoring,	 with	 no	 expectations	 of	 discharge	
(level	of	evidence	B).13
It should be kept in mind that follow-up with 
BM complements but does not replace clinical and 
dermoscopic examination of the entire skin surface. 
High-risk patients followed with BM should also be 
examined completely periodically by the dermatolo-
gist 13	(level	of	evidence	A).
Recommendations:
•	 	Follow-up	 with	 BM	 has	 benefits	 for	 patients	
with	 increased	 risk	 for	 melanoma	 (see	 text)	
(grade	of	recommendation	A).
Main	benefits	are:
Fewer	excisions	of	benign	lesions,	without	loss	
of	sensitivity	(grade	of	recommendation	A).
Allows	 diagnosis	 of	 thinner	 melanomas	 than	
those	diagnosed	in	individuals	not	subjected	to	such	
follow-up	(grade	of	recommendation	A).
•	  Follow-up with BM is not indicated for low-risk 
individuals because it reduces diagnostic speci-
ficity	and	results	in	a	greater	number	of	benign	
lesions unnecessarily excised (grade of recom-
mendation	B).
•	 	Isolated	suspicious	lesions	without	specific	crite-
ria	for	melanoma,	identified	in	low-risk	individ-
uals,	can	be	followed	with	short	term	BM,	which	
increases sensitivity for diagnosis of featureless 
melanoma	(grade	of	recommendation	A).
3) Is preventive excision of acral nevi beneficious 
to patients?
Acral	melanocytic	nevi	(AMN)	often	cause	con-
cern because it is widely accepted that they would 
have a higher risk of malignant transformation than 
those	 located	 elsewhere.	 It	 is	 also	known	 that	AMN	
frequently	present	cytological	and	architectural	atyp-
ia,	 with	 atypical	 junctional	 proliferation	 on	 histolo-
gy.41 There are no retrospective nor prospective stud-
ies	 indicating	 the	 frequency	 and	 types	 of	AMN	 that	
undergo	malignant	tranformation.	AMN	are	far	from	
uncommon	and	acral	melanoma	(AM)	is	less	common	
than other types of melanoma.42 The opinion among 
authors ranges from “only remove pigmentary lesions 
that	present	irregular	shape	or	color”,	to	“excise	every	
nevus	 of	 palmo-plantar	 region”,	 based	 on	 the	 ques-
tionable role of trauma in the development of melano-
ma in this region.43
Relation	between	presence	of	AMN	and	mela-
noma development in palmo-plantar region is contro-
versial. Rokuhara et al 44suggest that this relation is not 
significant	(level	of	evidence	A).	Koguchi	et	al	showed	
that	AMN	prevalence	in	patients	who	have	had	plan-
tar	AM	is	not	greater	than	the	control	group	(level	of	
evidence	A). 45 Green et al reported that patients with 
AM	have	 a	 large	numbers	of	nevi,	 including	acrally	
located	nevi	(level	of	evidence	A).46
It is a common belief that risk of developing 
AM	is	greater	in	African-Americans	and	Asians.	There	
are publications demonstrating a lower prevalence of 
AMN	 in	 Caucasians	 compared	with	African-Ameri-
cans. Palicka et al found palmar or plantar nevi in 42% 
of	African-Americans	versus	23%	of	Caucasians	(level	
of	evidence	B).	47 Furthermore,	while	CM	incidence	in	
all	sites	is	significantly	higher	in	Caucasians	(level	of	
evidence	A)	 incidence	 in	 acral	 regions	 is	 similar	 be-
tween	Caucasians	and	African-Americans	48,49 (level of 
evidence	B).	AM,	as	a	percentage	of	all	melanoma	cas-
es,	has	been	reported	in	60%	to	75%	of	African-Ameri-
can,	43%	to	49%	in	Asians,	and	5	to	7%	in	Caucasians.	
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50-52	CM	5-year	survival	rate	is	worse	in	African-Amer-
icans	compared	with	Caucasians,	but	when	stratified	
by	stage,	prognosis	is	similar	in	any	race,	suggesting	
that	diagnosis	in	African-Americans	tends	to	be	made	
at more advanced stages.49
Few case-control studies are available regarding 
AM	 risk	 factors,	which	 are	 suspected	 to	 differ	 from	
those	associated	with	CM	of	other	sites.	UV	radiation	
is	 thought	 to	 play	 an	 insignificant	 role	 among	AM.	
Green et al 46 and Rolon et al 53	identified	prior	trauma	
and	presence	of	preexisting	AMN	as	factors	associated	
with	the	occurrence	of	AM	(level	of	evidence	A).
Wong et al 54 and Phan et al 55 showed 10-27% 
histological	 contiguity	 between	 AM	 and	 junctional	
and dermal MN. The authors discuss that these val-
ues	should	demonstrate	a	downward	bias,	since	AM	
is usually diagnosed in advanced stages and might 
destroy	the	associated	nevi	(level	of	evidence	B).	Fur-
thermore,	recent	studies	suggest	that	AM	can	also	oc-
cur de novo.
Dermoscopy shows different pigment distri-
bution	in	AMN	and	in situ	AM,	indicating	that	these	
lesions arise from different portions of the epidermis 
and,	therefore,	would	develop	independently	56,57	(lev-
el	of	evidence	B).	Additionally,	a	genetic	mechanism	
was proposed for the development of de novo	 AM,	
which includes KIT mutation and cyclin D1 gene am-
plification	rather	than	the	previously	described	BRAF	
mutation,	suggesting	that	AM	did	not	originate	from	a	
nevus 58	(level	of	evidence	B).
Some authors consider nevi on the genitalia and 
perianal	region	as	acrally	located.	As	it	happens	with	
AMN,	preventive	removal	of	nevi	in	genital	and	peri-
anal	region	is	common.	This	is	justified	by	the	difficul-
ty	in	monitoring	the	lesion,	due	to	the	intimate	loca-
tion and reluctance in accepting examination. Hunt et 
al 59 performed a retrospective study in children with 
genital nevi and concluded that preventive biopsy is 
not necessary in the absence of clinical and dermato-
scopic suspicion. The authors found no association be-
tween	genital	nevi	and	risk	factors	for	melanoma,such	
as large number of nevi or family history of melano-
ma	(level	of	evidence	B).	Gleason	et	al	60 performed a 
clinicopathologic analysis of 56 nevi located on female 
genitalia	 and,	despite	 the	more	 frequent	presence	of	
histologic	 features	 of	 atypia	 than	 in	 other	 locations,	
they	followed	a	benign	course	(level	of	evidence	B).
Recommendations
•	 No studies evaluating the relationship be-
tween	 removal	of	AMN	and	benefits	 for	 the	
patient were found.
•	 There are reports of histologic contiguity be-
tween	 pre-existing	AM	 and	AMN.	 The	 pos-
sibility	of	AM	occuring	de novo makes it un-
necessary	 to	 biopsy	 every	 AMN	 (grade	 of	
recommendation	B).
•	 Recommendation for preventive resection of 
AMN	 on	 the	 genitalia	 and	 perianal	 region	
should follow the same approach of melano-
ma	cases	located	in	other	sites,	i.e.,	removal	of	
lesions with clinical or dermatoscopic suspi-
cion	(grade	of	recommendation	C).
4) Is preventive excision of congenital melanocyt-
ic nevi (CMN) beneficious to patients? 
The	concern	with	CMN	is	 justified	by	 the	risk	
of malignant transformation that it may present. It is 
known that the risk is proportional to the dimensions 
of	the	CMN,	what	makes	the	classification	of	 lesions	
according	to	size	to	assume	practical	importance.	The	
most	accepted	classification	is	 the	one	that	considers	
the largest diameter reached by CMN in adulthood: 
small	<1.5	cm;	medium	=	1.5-19.9	cm;	and	giant	>20.0	
cm. 61 Considering that nevus growth is proportional 
to	the	child’s	body,	it	can	be	estimated	that	a	nevus	on	
the	head	or	the	body	of	a	newborn	of	>9	cm	and	>6	cm,	
respectively,	will	be	giant	in	adulthood.	62,63
The risk of malignant transformation was over-
estimated	for	some	time.	Giant	CMN	(G-CMN)	pres-
ent a probable risk throughout life of <5%64-66 (level of 
evidence	B).	On	the	contrary	small	or	medium	CMN	
(S/M-CMN)	 present	 a	 low	 risk	 of	melanoma	 devel-
opment,	close	to	that	observed	for	general	population	
67,68	 (level	 of	 evidence	 C).	 Thus,	 malignization	 risk,	
even	for	G-CMN,	is	not	so	high	to	make	prophylactic	
excision of these lesions mandatory and dogmatic.
Classically,	 melanoma	 risk	 in	 G-CMN	 is	 re-
ferred	as	higher	 in	 the	first	years	of	 life,	when	mon-
itoring should be more rigorous. In 55% of patients 
with	G-CMN	who	develop	melanoma,	tumor	appears	
in	 the	first	five	years	of	 life	and	70%	before	puberty	
69,70	 (level	 of	 evidence	 B).	 Evidences	 in	 the	 literature	
are	insufficient	for	safe,	consensual	recommendation,	
either	 for	preventive	 removal	of	 these	 lesions,	or	 for	
expectant	management	(level	of	evidence	A).	64,65,67,71-74 
Studies about S/M-CMN are much more scarce 
and	full	of	methodological	challenges,	also	leading	to	
inaccurate	 risk	of	melanoma,	but	 close	 to	 the	 risk	of	
the general population. In these cases the risk is appar-
ently	higher	after	puberty,	since	S/M-CMN	associat-
ed melanoma tends to occur commonly in adulthood 
75	(level	of	evidence	C).	Furthermore,	melanoma	tends	
to	 be	 more	 superficial,	 (origin	 at	 the	 dermo-epider-
mal	 junction),	which	may	facilitate	 its	detection,	and	
occurs preferably at the periphery of nevus (level of 
evidence	C). 75-78 
G-CMN associated melanoma can have a deep-
er	origin	in	the	skin	(dermis),	presenting	as	a	tumor	or	
nodule.	The	presence	of	these,	especially	if	firm,	hard-
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ened	and	adherent,	with	fast	growth	history,	associat-
ed	or	not	with	adenopathy,	should	be	observed	with	
caution.	If	that	is	the	case,	performing	a	biopsy	should	
be	 considered.	 Neuroid	 tumors,	 such	 as	 neurofibro-
mas	and	schwannomas,	common	in	G-CMN,	general-
ly present elastic and movable consistency. Palpation 
of skin and lymph node chain is an essential step of 
the physical examination of these patients.
Apparently,	 G-CMN	 lesions	 that	 carry	 in-
creased risk of malignancy are those located in the axis 
(trunk,	head/neck),	especially	the	large	ones	(>40	cm)	
with numerous satellite lesions. 79	 Approximatively	
75% of G-CMN associated melanomas occur in nevi 
with “bathing suit” distribution.74,75	Moreover,	nevus	
restricted to limbs present reduced risk of malignan-
cy,	 as	well	 as	 those	 in	 individuals	with	 few	 satellite	
lesions. The malignant transformation of satellites le-
sions	 (found	 in	80%	of	patients	with	G-CMN)	 is	 im-
probable.	Clinical	significance	of	satellite	lesions	is	to	
translate increased risk of neurological involvement 
(Neurocutaneous	melanosis	 -	NCM)	 and	melanoma,	
when	present	in	large	numbers	(>50).
Paradoxically,	G-CMN	 lesions	with	 higher	 risk	
of	 melanoma,	 which	 removal	 could	 theoretically	 be	
beneficial,	are	difficult	to	excise,	either	because	of	nevus	
dimension,	which	can	compromise	a	significant	area	of	
the	tegument,	or	because	nevus	cells	are	located	deeper	
into	the	skin,	sometimes	reaching	the	muscular	fascia.
It must be remembered that melanoma risk is 
not	limited	to	the	skin	or	nevi,	but	may	also	occur	in	
extra-cutaneous	sites,	especially	in	the	central	nervous	
system.	In	such	case,	it	is	refered	to	as	neuro-cutane-
ous	 melanosis	 (NCM),	 defined	 as	 melanocytic	 pro-
liferation of benign or malignant lesions in the lep-
tomeninges,	most	commonly	associated	with	G-CMN.	
Thus,	complete	removal	of	G-CMN	does	not	stop	the	
risk	of	melanoma,	because	 it	 is	unfeasible	 to	remove	
all nevus cells in extra-cutaneous sites.
Management	of	CMN	should	be	individualized	
and	discussed	with	 the	patient	and	family,	consider-
ing,	in	addition	to	melanoma	risk,	other	aspects	such	
as	age,	location	of	the	nevus,	size	and	depth,	clinical	
appearence	 (especially	 color	 and	 surface),	 personal	
and	 family	 risk	 of	 melanoma,	 aesthetic	 impact	 and	
patient’s desire or not to remove the nevus (level of 
evidence	B).	63,64,66,68,71 
Recommendations
a) Small or medium CMN
•		There	 is	 no	 dogmatic	 approach.	 As	 well	 as	
melanoma	 risk,	 factors	 such	 as	 age,	 location	
(especially	in	difficult	self-examination	areas),	
size,	 clinical	and	dermoscopic	appearance	of	
the	 nevus,	 history	 of	 modification,	 presence	
of	 other	 risk	 factors	 for	melanoma,	 aesthetic	
impact and patient desire must be taken into 
consideration	(grade	of	recommendation	A).
•		When	 surgical	 excision	 is	 the	 option,	 it	 is	
should preferably be performed from 7-8 
years	 until	 puberty,	 when	 the	 child	 already	
collaborates with the procedure under local 
anesthesia	(grade	of	recommendation	C).
•	 Photographic monitoring and digital dermo-
scopic	evaluation	(especially	of	smaller	nevi)	
are very useful in the clinical management of 
these	patients	(grade	of	recommendation	C).
b) Giant CMN
•		G-CMN	removal,	when	desired	and	feasible,	
must	be	 early,	 since	 the	 risk	of	melanoma	 is	
apparently greater in childhood (grade of rec-
ommendation	B).
•		When	 indicated,	 intervention	 should	be	per-
formed	after	the	first	six	months	of	life	due	to	
the risk of anesthetic complications in this age 
group	(grade	of	recommendation	C).
•		Although	 the	 risk	 is	 apparently	 higher	 in	
childhood	and	adolescence,	 it	 is	advisable	to	
keep	track	during	adulthood,	because	the	risk	
remains throughout life (grade of recommen-
dation	B).
•		Patients	with	NCM	do	not	benefit	 from	exci-
sion	of	the	nevus	(grade	of	recommendation	B).
•	 The approach of the G-CMN should be mul-
tidisciplinary	 (dermatologists,	 pediatricians,	
plastic	 surgeons,	 neurologists	 and	 psycholo-
gists,	among	other	professionals)	and	individ-
ualized	for	each	patient	(grade	of	recommen-
dation	B).
•	 Histologic interpretation of G-CMN associ-
ated	 nodes	 (especially	 in	 children	 <1	 year)	
should be performed by experienced derma-
topathologists since they often simulate mela-
noma	(grade	of	recommendation	B).
5) How should stages 0 and I primary cutaneous 
melanoma patients be followed?
The	 potential	 aggressiveness	 of	 CM	 justifies	
the follow-up of patients after completion of neces-
sary	 therapeutic	 measures.	 The	 main	 objectives	 of	
follow-up are two: to reduce morbidity and mortali-
ty through early detection of disease progression and 
to search for new primary lesions. Every patient di-
agnosed with CM should be staged according to the 
recommendations	 of	 the	American	 Joint	 Committee	
on	Cancer	(7th	edition)	(level	of	evidence	A). 80
In stage I are included patients with invasive 
melanoma	 and	 Breslow	 thickness	 <1.0	 mm	 (T1),	 as	
well as patients with melanomas and Breslow thick-
ness	1,1	mm	to	2.0	mm,	but	not	exhibiting	ulceration	
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or	positive	mitotic	index	(T2a).	Stage	0	corresponds	to	
patients with in situ  melanoma .
Patients diagnosed with stage I PCM have less 
chance of relapse compared with more advanced stag-
es. Patients with T1 and T2 tumors present 10-year 
survival	rates	of	92%	and	80%,	respectively.	For	stage	
0 patients the survival rate is almost 100%.80
Soon after diagnosis a careful history should 
be	 taken	 (clinical	history	 and	physical	 examination),	
followed by guidance on melanoma and its potential 
consequences.	Furthermore,	an	adequate	level	of	un-
derstanding on the aspects of the disease must be ac-
quired	by	patients	and	a	constant	dialogue,	accessible	
and	understandable	to	their	level	of	knowledge,	must	
be	offered	during	 the	period	of	 follow-up,	clarifying	
issues	related	to	the	disease.	Appropriate	orientation	
regarding the possibility of relapse or appearance of 
new	primary	 lesions,	 social	 issues	 and	primary	pre-
ventive care for individuals and their families should 
also	be	given.		(level	of	evidence	D). 81-83
Patients with stage II PCM should conduct pe-
riodic	clinical	examination,	consisting	of	general	skin	
assessment and palpation of lymph nodes. There is no 
consensus	 on	 the	 frequency	 of	 this	 assessment.	Rec-
ommendations are that it should be performed 2-4 
times	a	year	during	the	first	5	years	after	diagnosis	and	
once a year until completing 10 years of follow-up. 
Frequency	may	depend	on	factors	such	as	presence	of	
multiple	 primary	 melanomas	 (MPM),	 atypical	 nevi,	
family	history,	patient	anxiety	and	ability	to	recognize	
recurrences	or	new	lesions	(evidence	level	D).	8,82-84 In 
more	 than	 half	 of	 patients	with	 relapses,	 lesions	 are	
detected	by	the	patients	themselves,	thus	they	should	
be taught to perform self-examination of the skin and 
lymphatic chains in search of suspicious lesions (level 
of	evidence	C).82,85-87
Patients	in	stage	0	apparently	do	not	require	pe-
riodic	clinical	examination,	since	disease	progression	
is	unlikely	(level	of	evidence	C).22,86  The possibility of 
MPM must be taken into consideration for such pa-
tients,	 therefore	stage	0	PCM	patients	should	receive	
information and perform self-examination of the skin 
and general examination of skin annually (level of ev-
idence	D).
Although	 some	 authors	 indicate	 laboratory	
tests (especially serum lactate dehydrogenase and al-
kaline	phosphatase),	 the	majority	 suggests	 that	 such	
exams should not be performed routinely in patients 
in	stage	I	(level	of	evidence	C).8,22,81-83,88  S100 serum lev-
els was observed as a potential predictor of advanced 
disease in patients with CM. Patients with stage I to III 
can present it as a progression marker. In places where 
S100serum	levels	is	available,	the	recommendation	is	
to use it. Patients with stage 0 do not need to perform 
additional	tests	(level	of	evidence	C).22,86,88,89
There	is	little	evidence	of	benefits	in	performing	
imaging exams for stage I PCM patients. Chest X-ray 
appears	 not	 to	 provide	 benefits	 when	 performed	 in	
routine.	It	may	identify	false-positive	lesions,	present-
ing low possibility of detection of lesions with surgical 
potential	to	modify	survival,	besides	not	being	able	to	
diagnose early lung metastases. Sometimes it causes 
anxiety in patients. Patients with stage 0 do not re-
quire	imaging	(level	of	evidence	C).90-93
Abdominal	ultrasound	(US)	is	also	not	routinely	
recommended for asymptomatic stage I PCM patients. 
Cost-effectiveness is low for metastases detection in 
this	group	of	patients	 (level	of	evidence	C). 89-92	Axil-
lary	 and	 inguinal	 US-proven	 lymph-nodes,	 in	 some	
studies,	 to	 be	 superior	 to	 palpation	 in	 the	 detection	
of	metastases.	Thus,	its	use	may	be	indicated	for	this	
group	of	patients,	especially	 those	with	Ib	or	 thicker	
tumors,	always	considering	the	cost-effectiveness	and	
availability	 of	 the	 method,	 as	 well	 as	 the	 ability	 of	
professionals	to	perform	it	(level	of	evidence	C).22,86,94-
97		CT	scan	also	presents	little	benefit	for	patients	with	
thin	CM,	 adding	 significant	 rates	 of	 radiation	 expo-
sure 98	(level	of	evidence	C).	It´s	use	should	be	restrict-
ed for patients with suspicion of recurrence based on 
clinical and/or imaging examination conducted with 
a	less	accurate	method	(level	of	Evidence	D).
PET scan seems to have higher resolution to de-
tect	suspicious	lesions,	but	given	the	low	probability	
of	disease	progression	in	stages	0	and	I,	the	vast	ma-
jority	of	tests	conducted	in	patients	with	early	CM	are	
normal,	and	false	positives	may	occur;	thus	this	exam-
ination is not recommended on a routine basis 99 (level 
of	evidence	C).
Finally,	most	authors	suggest	that	complemen-
tary and imaging tests should be performed only in 
patients with stage I PCM who are symptomatic and 
present suspicion of tumor recurrence on physical ex-
amination	(level	of	evidence	D).	8,22,81-83
Recommendations:
•		All	patients	diagnosed	with	melanoma	should	
be evaluated clinically and staged according 
to	 the	AJCC	 TNM	 system	 (grade	 of	 recom-
mendation	A).	
•	 Stage 0 melanoma patients do not need fol-
low-up with laboratory or imaging tests 
(grade	of	recommendation	C).
•	 Stage II melanoma patients should perform 
clinical evaluation of the skin and lymph 
nodes	regularly	(2-4	times	a	year)	in	the	first	
5 years after diagnosis of melanoma and once 
a year until completing 10 years of follow-up 
(grade	of	recommendation	D).
•	 Laboratory and imaging tests should be per-
formed only for patients with stage I mela-
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noma who present symptomatic or suspicion 
of	disease	recurrence,	according	to	the	physi-
cian’s choice and tests availability (grade of 
recommendation	C).
•		US	of	lymph	node	chains	(level	of	evidence	C)	
and	dosage	of	S100	serum	levels	may	be	valid,	
even	in	asymptomatic	patients,	if	they	present	
stage	Ib	or	higher,	and	according	to	the	avail-
ability and accessibility of the method (grade 
of	recommendation	C).
At	 the	 end	 of	 the	 presentation	 of	 this	 second	
part	of	the	Brazilian	guidelines	on	melanoma,	it	is	very	
important to highlight that these guidelines are not in-
tended	to	restrain	medical	practice,	but	make	it	more	
homogeneous,	reducing	uncertainty/disagreement	of	
good	practice	standards.	By	establishing	standards,	in	
addition	to	reducing	the	differences	in	care,	it	 is	also	
possible	to	provide	options	based	on	evidence,	allow-
ing the physician to make decisions about treatment 
or	diagnostic	methods,	reducing	the	strain	on	patients,	
doctors and health system.
These	 guidelines	 reflect	 the	 best	 scientific	 in-
formation	published	on	 the	 subject	 until	 the	date	 of	
its	preparation.	Nevertheless,	 these	data	must	be	 in-
terpreted	carefully,	since	the	results	of	 future	studies	
could lead to changes in recommendations. In some 
cases,	these	guidelines	should	not	be	followed,	always	
keeping in mind the patient’s well being as well as 
other special circumstances. It is also important to re-
member that it is out of the scope of these guidelines 
to	discuss	aspects	of	prevention	of	skin	cancers,	such	
as	use	of	sunscreen	and	other	measures,	which	should	
be	discussed	in	a	specific	article.q
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